183 related articles for article (PubMed ID: 3528213)
1. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole.
Hoeprich PD; Merry JM
J Clin Microbiol; 1986 Aug; 24(2):269-71. PubMed ID: 3528213
[TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts.
Fromtling RA; Yu HP; Shadomy S
Mycopathologia; 1984 Apr; 86(1):45-50. PubMed ID: 6330557
[TBL] [Abstract][Full Text] [Related]
3. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
Fromtling RA; Abruzzo GK; Bulmer GS
Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339
[TBL] [Abstract][Full Text] [Related]
4. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts.
Doern GV; Tubert TA; Chapin K; Rinaldi MG
J Clin Microbiol; 1986 Oct; 24(4):507-11. PubMed ID: 3533974
[TBL] [Abstract][Full Text] [Related]
5. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.
Chen SC; O'Donnell ML; Gordon S; Gilbert GL
J Antimicrob Chemother; 1996 Feb; 37(2):265-73. PubMed ID: 8707736
[TBL] [Abstract][Full Text] [Related]
6. Fluconazole, itraconazole and ketoconazole in-vitro activity. A comparative study.
Arzeni D; Barchiesi F; Ancarani F; Scalise G
J Chemother; 1991 Jun; 3(3):139-42. PubMed ID: 1655990
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.
Davey KG; Szekely A; Johnson EM; Warnock DW
J Antimicrob Chemother; 1998 Oct; 42(4):439-44. PubMed ID: 9818741
[TBL] [Abstract][Full Text] [Related]
8. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts.
Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G
Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole.
Torres-Rodríguez JM; Mendez R; López-Jodra O; Morera Y; Espasa M; Jimenez T; Lagunas C
Antimicrob Agents Chemother; 1999 May; 43(5):1258-9. PubMed ID: 10223946
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
11. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA
J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817
[TBL] [Abstract][Full Text] [Related]
12. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002.
Shadomy S; Espinel-Ingroff A; Kerkering TM
Sabouraudia; 1984; 22(1):7-15. PubMed ID: 6322364
[TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activity of saperconazole (R 66905) against Candida and Torulopsis.
Mallié M; Montès B; Lebecq JC; Bastide JM
Mycoses; 1989 Dec; 32(12):631-7. PubMed ID: 2695841
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test.
Simor AE; Goswell G; Louie L; Lee M; Louie M
Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):693-7. PubMed ID: 9352266
[TBL] [Abstract][Full Text] [Related]
15. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.
Peng T; Galgiani JN
Antimicrob Agents Chemother; 1993 Oct; 37(10):2126-31. PubMed ID: 8257134
[TBL] [Abstract][Full Text] [Related]
16. The influence of antifungal antibiotics on some determinants of virulence in Candida albicans and Cryptococcus neoformans cells.
Borowski J; Jakoniuk P; Jablońska W; Jakubicz W; Szpak A
Experientia; 1974 Oct; 30(10):1210-1. PubMed ID: 4611784
[No Abstract] [Full Text] [Related]
17. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester.
Hoeprich PD; Huston AC
J Infect Dis; 1976 Oct; 134(4):336-41. PubMed ID: 789787
[TBL] [Abstract][Full Text] [Related]
18. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media].
Tapia C; León E; Palavecino E
Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079
[TBL] [Abstract][Full Text] [Related]
19. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of two new antifungal azoles.
Hoeprich PD; Merry JM
Antimicrob Agents Chemother; 1984 Mar; 25(3):339-41. PubMed ID: 6721465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
